Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Neurology|May 2, 2013
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMSJeffrey A Cohen, Frederik Barkhof, Giancarlo Comi, et al.Multiple Sclerosis and Related Disorders|October 23, 2017
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO studyPatricia K Coyle, Bhupendra Khatri, Keith R Edwards, et al.Multiple Sclerosis and Related Disorders|October 2, 2018
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practicePatricia K Coyle, Bhupendra Khatri, Keith R Edwards, et al.Multiple Sclerosis and Related Disorders|April 22, 2019
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO studyPatricia K Coyle, Bhupendra Khatri, Keith R Edwards, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 27, 2015
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A Cohen, Bhupendra Khatri, Frederik Barkhof, et al.Journal of Comparative Effectiveness Research|February 14, 2019
Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR studyRobert Zivadinov, Kiren Kresa-Reahl, Bianca Weinstock-Guttman, et al.The Lancet. Neurology|May 17, 2011
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyBhupendra Khatri, Frederik Barkhof, Giancarlo Comi, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|November 21, 2022
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT studySibyl Wray, Francois Jacques, Tamara A Miller, et al.Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 23, 2020
Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosisGuy Buckle, Daniel Bandari, Jeffrey Greenstein, et al.Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.Pageof 2